XellSmart gets fourth consecutive IND clearances for iPSC cell therapy trials
XellSmart Pharmaceutical secured fourth consecutive IND clearances from the US FDA and China’s National Medical Products Administration for a Phase I/II trial of an allogeneic, off‑the‑shelf iPSC‑derived neuronal progenitor therapy targeting multiple system atrophy–Parkinsonian type (MSA‑P). The company previously won INDs for Parkinson’s disease, spinal cord injury and ALS, and expects the MSA‑P programme to begin trials in 2026.
Why it mattersFDA and NMPA cleared a Phase I/II IND for XellSmart’s iPSC MSA‑P therapy.
Entities Mentioned
XellSmart Pharmaceutical Co., LtdUS Food and Drug Administration